Hans Gelderblom, MD, PhD (he/him/his)

Medical Oncologist
Leiden University Medical Center, Netherlands

Prof Hans Gelderblom is chair of the department of medical oncology at the Leiden University Medical Center (LUMC) in the Netherlands and of the comprehensive regional cancer center (https://www.universiteitleiden.nl/en/staffmembers/hans-gelderblom#tab-1).

He is former chair of the the EORTC Soft Tissue and Bone Sarcoma Group. The LUMC is the (co)leading institution for the EU project Personalised Cancer Medicine for all EU citizens (https://www.matrix-fkb.no/en/pcm4eu/home) and implementation project PRIME-ROSE .

The LUMC is a specialised center in bone and soft tissue sarcoma, including GIST and also hosting the Dutch Bone Tumour Committee. Due to the close collaboration in the sarcoma team and vast clinical trial unit experience, the LUMC developed into one of the world leading institutes on the development of CSF-R1 inhibitors, such as vimseltinib, for diffuse type tenosynovial giant cell tumours, which is the subject of his oral presentation at CTOS 2023.

Poster(s):

• (P 27) A MULTICENTER RETROSPECTIVE STUDY ON THE CLINICAL BEHAVIOR OF SDH-DEFICIENT GIST

• (P 30) FINANCIAL DIFFICULTIES EXPERIENCED BY DUTCH GASTROINTESTINAL STROMAL TUMOR (GIST) PATIENTS: DATA FROM A CROSS-SECTIONAL MULTICENTER STUDY

• (P 55) RELATIVE WASH-IN RATE ON DYNAMIC CONTRAST-ENHANCED MRI AS A NEW PROGNOSTIC FACTOR IN PATIENTS WITH OSTEOSARCOMA; A POSSIBLE TOOL FOR PERSONALIZED SARCOMA-CARE?

• (P 56) CHARACTERIZATION OF DENOSUMAB TREATMENT RESPONSE ON MR PERFUSION IN GIANT CELL TUMORS OF BONE

• (P 73) FOSTER CONSORTIUM, FIGHT OSTEOSARCOMA THROUGH EUROPEAN RESEARCH

• (P 138) CONTROVERSIES IN THE MANAGEMENT OF PATIENTS WITH SOFT TISSUE SARCOMA: RESULTS AND RECOMMENDATIONS FROM THE FIRST CONFERENCE ON STATE OF SCIENCE IN SARCOMA (CSSS)

• (P 173) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE

• (P 176) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE

• (P 369) MAGEA ANTIGENS AS IMMUNOTHERAPEUTIC TARGETS FOR ADVANCED OSTEOSARCOMA

• (P 451) IMPACT OF TIME TO DIAGNOSIS - A PROSPECTIVE ANALYSIS OF THE EWING 2008 TRIAL

• (P 543) MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR